Tag:

China

Latest Headlines

Latest Headlines

Ascletis plans China, Taiwan PhIII trials on chronic hep C therapies

China-based Ascletis Pharmaceuticals has notched up a first with plans for Phase III trials of danoprevir (ASC08) and ASC16 (PPI-668) to treat chronic hepatitis C in China and Taiwan. If successful, the trials could represent a milestone that could reach an estimated patient population of 30 million to 40 million, the highest worldwide.

EU slaps Chinese amoxicillin maker with import ban

China's hit-and-miss government oversight poses special challenges for drug regulators who too often find companies there skirting the standards they expect. For the second time this year, European regulators have put a halt on exports from a Chinese company that they discovered had serious problems.

China not only source for counterfeit drugs but also for meth, other synthetics

The FDA once again pitched in last week with other international regulators to crack down on illegal and counterfeit drugs being peddled over the internet. The FDA, Interpol and other authorities seized drugs, shut down some websites and made some arrests.

Europe bans some APIs from Chinese drugmaker Zhuhai United

China's Zhuhai United Laboratories bills itself as the world's largest manufacturer of the API for the antibiotic amoxicillin. But the sterile manufacturing for some of its amoxicillin products has been called into question by inspectors in Europe, which is banning the sterile drugs for now, except in limited cases.

Newly HK-listed 3SBio buys ex-China rights to Apexigen MAB candidate

Recently listed in Hong Kong 3SBio said it has bought the ex-China rights to Apexigen's anti-TNF monoclonal antibody technology, adding to mainland rights held since 2006.

China's BeiGene gets U.S. FDA IND nod on oncology candidate BGB-3111

China's BeiGene has received U.S. FDA approval on an IND application for clinical development of BGB-3111, a proprietary Bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies, putting a fresh round of funds to use as it works on three main oncology candidates.

Beijing-Washington eye investment pact as China's U.S. tech buys pay off

A steady march of investments in U.S. high-technology sectors by Chinese companies from telecom to biotech will come into focus this week in high-level talks in Washington, DC, that will cover a proposed bilateral investment treaty, Reuters reports.

China academy-sponsored study says Pearl River a hot spot of antibiotic residue

China's Pearl River flows with residues of three dozen types of common antibiotics widely consumed by top-user China, a Chinese Academy of Sciences-sponsored study found. The study suggests that overuse by humans and animals is the main driver causing densely populated areas to see high concentrations of antibiotic residue.

Chinese med tech gets the WHO's OK for circumcision device

China is a hotbed of med tech growth, with local companies competing against foreign devicemakers for their cut of the profits. One Chinese company got a boost in the race, as the World Health Organization (WHO) approved Wuhu SNNDA Medical Treatment Appliance Technology's circumcision device for HIV prevention.

A heavier China drives cardio, diabetes and healthcare reforms

Rising cardiovascular disease rates in China are directly linked to a change in diet as incomes drive up demand for processed meat with high salt content. That and other dietary changes are creating a heavier population and driving government healthcare cost reforms, Xinhua reports.